Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses.
oncolytic viruses
tumor microenvironment
tumor stroma
virotherapy
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
05 Nov 2020
05 Nov 2020
Historique:
received:
20
10
2020
revised:
02
11
2020
accepted:
03
11
2020
entrez:
10
11
2020
pubmed:
11
11
2020
medline:
11
11
2020
Statut:
epublish
Résumé
Current cancer therapeutics often insufficiently eradicate malignant cells due to the surrounding dense tumor stroma. This multi-componential tissue consists of mainly cancer-associated fibroblasts, the (compact) extracellular matrix, tumor vasculature, and tumor-associated macrophages, which all exert crucial roles in maintaining a pro-tumoral niche. Their continuous complex interactions with tumor cells promote tumor progression and metastasis, emphasizing the challenges in tumor therapy development. Over the last decade, advances in oncolytic virotherapy have shown that oncolytic viruses (OVs) are a promising multi-faceted therapeutic platform for simultaneous tumor and stroma targeting. In addition to promoting tumor cell oncolysis and systemic anti-tumor immunity, accumulating data suggest that OVs can also directly target stromal components, facilitating OV replication and spread, as well as promoting anti-tumor activity. This review provides a comprehensive overview of the interactions between native and genetically modified OVs and the different targetable tumor stromal components, and outlines strategies to improve stroma targeting by OVs.
Identifiants
pubmed: 33167307
pii: biomedicines8110474
doi: 10.3390/biomedicines8110474
pmc: PMC7694393
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Nat Rev Drug Discov. 2019 Sep;18(9):689-706
pubmed: 31292532
Front Cell Dev Biol. 2019 Apr 24;7:60
pubmed: 31106200
Mol Ther Oncolytics. 2019 Nov 02;15:234-247
pubmed: 31872046
Mol Ther Oncolytics. 2015 Mar 18;2:15003
pubmed: 27119102
Nat Biotechnol. 2012 Jul 10;30(7):658-70
pubmed: 22781695
J Clin Invest. 2010 May;120(5):1551-60
pubmed: 20364090
Laryngoscope. 2009 Apr;119(4):665-74
pubmed: 19213040
Nat Med. 2015 May;21(5):530-6
pubmed: 25894825
Cancer Res. 2008 Feb 15;68(4):1170-9
pubmed: 18281493
Cancer Discov. 2019 Feb;9(2):282-301
pubmed: 30366930
Front Mol Biosci. 2020 Jan 31;6:160
pubmed: 32118030
Curr Opin Biotechnol. 2016 Aug;40:41-48
pubmed: 26938687
Cancers (Basel). 2020 May 21;12(5):
pubmed: 32455560
J Virol. 2003 Feb;77(4):2640-50
pubmed: 12552003
Int J Mol Sci. 2019 Oct 07;20(19):
pubmed: 31591367
Cancer Cell. 2015 Aug 10;28(2):210-24
pubmed: 26212250
Med Oncol. 2017 Jul;34(7):129
pubmed: 28593604
Nat Rev Drug Discov. 2019 Feb;18(2):99-115
pubmed: 30470818
Med Clin North Am. 2017 Nov;101(6):1053-1073
pubmed: 28992854
Cancer Cell. 2014 Jun 16;25(6):735-47
pubmed: 24856585
Cancer Res. 2009 Feb 15;69(4):1459-68
pubmed: 19208845
Oncolytic Virother. 2015 Nov 11;4:169-81
pubmed: 27512680
Hum Gene Ther. 2005 Jun;16(6):765-78
pubmed: 15960607
Virus Res. 2015 Nov 2;209:56-66
pubmed: 26221764
J Virol. 2010 Jan;84(2):856-66
pubmed: 19906926
EBioMedicine. 2018 May;31:17-24
pubmed: 29724655
Mol Ther Oncolytics. 2019 Oct 24;15:214-222
pubmed: 31890868
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Mol Ther. 2012 Jan;20(1):54-62
pubmed: 21863000
J Exp Med. 2017 Mar 6;214(3):579-596
pubmed: 28232471
Cell. 2018 Feb 8;172(4):841-856.e16
pubmed: 29395328
Mol Cancer Res. 2017 Oct;15(10):1410-1420
pubmed: 28679779
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Expert Opin Biol Ther. 2020 Oct;20(10):1187-1201
pubmed: 32602788
Cancer Discov. 2019 Aug;9(8):1102-1123
pubmed: 31197017
Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):E1291-300
pubmed: 23509246
Arch Pharm Res. 2018 Jul;41(7):711-724
pubmed: 29961196
World J Clin Cases. 2019 Aug 26;7(16):2143-2154
pubmed: 31531310
Immunity. 2020 Jan 14;52(1):36-54
pubmed: 31940272
Converg Sci Phys Oncol. 2017;3:
pubmed: 30079253
Virulence. 2013 Jan 1;4(1):85-9
pubmed: 23314571
Cancer Gene Ther. 2014 Feb;21(2):68-73
pubmed: 24434571
Eur J Cancer. 2008 Sep;44(13):1904-13
pubmed: 18691882
J Cell Biol. 2006 Jul 31;174(3):323-7
pubmed: 16880267
Front Oncol. 2020 Jan 24;9:1512
pubmed: 32039007
Cancer Res. 2000 Feb 15;60(4):1111-6
pubmed: 10706132
Expert Opin Biol Ther. 2019 Jun;19(6):561-573
pubmed: 30919708
J Natl Cancer Inst. 2017 Apr 1;109(4):
pubmed: 28376158
Int J Oncol. 2019 Feb;54(2):407-419
pubmed: 30570109
Oncoimmunology. 2019 Apr 13;8(7):1596004
pubmed: 31143517
Cancer Microenviron. 2019 Apr;12(1):37-46
pubmed: 31025289
Viruses. 2018 Aug 11;10(8):
pubmed: 30103501
J Immunother Cancer. 2018 Dec 4;6(1):140
pubmed: 30514385
Oncol Lett. 2018 Apr;15(4):4053-4060
pubmed: 29541169
PLoS One. 2009;4(4):e5119
pubmed: 19337591
Int J Cancer. 2014 Sep 1;135(5):1238-46
pubmed: 24474587
J Immunother Cancer. 2019 Jan 25;7(1):19
pubmed: 30683154
Virus Res. 2019 Sep;270:197675
pubmed: 31351879
Cancer Res. 2007 Jan 15;67(2):440-4
pubmed: 17234749
Biomedicines. 2014 Apr 17;2(2):163-194
pubmed: 28548066
J Control Release. 2014 Oct 28;192:148-56
pubmed: 25037019
Oncogene. 2015 Jul;34(28):3617-26
pubmed: 25263438
Front Immunol. 2019 Aug 02;10:1835
pubmed: 31428105
Gene Ther. 2010 Oct;17(10):1200-5
pubmed: 20463757
Int J Cancer. 2006 Jul 15;119(2):328-38
pubmed: 16470838
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Nat Med. 2000 Jul;6(7):821-5
pubmed: 10888934
Proteomics. 2018 Mar;18(5-6):e1700167
pubmed: 29280568
Mol Cancer Ther. 2005 Sep;4(9):1399-408
pubmed: 16170032
BMC Cancer. 2017 Dec 05;17(1):823
pubmed: 29207990
Adv Exp Med Biol. 2018;1060:99-114
pubmed: 30155624
Mol Ther. 2011 May;19(5):886-94
pubmed: 21364541
Cancers (Basel). 2018 Sep 26;10(10):
pubmed: 30261620
Cancer Res. 2018 Dec 15;78(24):6852-6865
pubmed: 30449733
Nat Rev Clin Oncol. 2018 Jun;15(6):366-381
pubmed: 29651130
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Cancer Res. 2013 Feb 15;73(4):1265-75
pubmed: 23393196
Mol Ther. 2008 Aug;16(8):1382-91
pubmed: 18545226
Clin Cancer Res. 2006 Nov 15;12(22):6791-9
pubmed: 17121900
Sci Rep. 2018 Dec 6;8(1):17683
pubmed: 30523283
Cancer Sci. 2017 Oct;108(10):1921-1926
pubmed: 28763139
Cytokine Growth Factor Rev. 2018 Jun;41:28-39
pubmed: 29576283
Semin Cancer Biol. 2018 Oct;52(Pt 2):189-197
pubmed: 29501787
J Clin Med. 2020 Jan 08;9(1):
pubmed: 31936317
Cytokine. 2009 Sep;47(3):199-205
pubmed: 19640730
Cytokine Growth Factor Rev. 2020 Jul 3;:
pubmed: 32718830
Cancers (Basel). 2020 Jul 21;12(7):
pubmed: 32708142
Gut. 2013 Jan;62(1):112-20
pubmed: 22466618
Front Oncol. 2017 Sep 11;7:202
pubmed: 28955655
Front Cell Dev Biol. 2018 May 08;6:48
pubmed: 29868579
Front Biosci. 2006 Jan 01;11:479-91
pubmed: 16146745
J Invest Dermatol. 2013 Nov;133(11):2576-2584
pubmed: 23604101
J Cancer Res Clin Oncol. 2019 Mar;145(3):765-774
pubmed: 30666409
Cancer Gene Ther. 2013 Jan;20(1):17-24
pubmed: 23138870
BMC Cancer. 2012 Aug 23;12:366
pubmed: 22917220
Cancer Lett. 2015 Sep 1;365(2):240-50
pubmed: 26052095